Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-16

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates newly diagnosed multiple myeloma patients following standard of care treatment. The primary endpoint of the study is to determine minimal residual disease (MRD) by combining 2 techniques in order to better predict progression free survival (PFS) of a patient. Secondary endpoint is to gain more insight into diagnostic features to better stratify patients based on risk factors for early relapse. Both endpoints could lead to a more patient specific treatment in the future.

Participants will be followed throughout their standard of care treatment. This treatment consists of indcution chemotherapy, followed by autologous stem cell transplant (ASCT), followed by lenalidomide maintenance therapy.

* Before start of induction chemotherapy the patient will receive a whole-body FDG PET/LDCT scan and an additional bone marrow aspirate sample will be taken during a routine bone marrow punction. This sample will be used for whole exome sequencing (WES).
* For those patients who achieve at least a very good partial response (VGPR) after induction chemotherapy and ASCT a repeat whole body FDG PET/LDCT scan will be performed before start of maintenance therapy. This scan will be repeated for a third time after 1 year of maintenance therapy. Besides this, an additional bone marrow aspirate sample will be taken for MRD detection. This will be done before start of maintenance therapy, after 1 year of maintenance therapy and after 2 years of maintenance therapy. MRD detection is done by next generation flow cytometery (NGF).
* During mantenance therapy patient follow-up will be performed at least every 3 months to determine best response to therapy or possible relapse (based on routine lab information).
* Those patients who do not achieve VGPR or better will not need to receive a whole body FDG PET/CT scan and MRD detection by flow cytometry, but these patients will undergo the same follow-up during maintenance therapy.
* In case of relapse, for all patients, an additional bone marrow aspirate sample will be taken for WES (during a routine bone marrow investigation).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner

NCT05381077

Multiple Myeloma Bone Metastases

UNKNOWN NA

Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI

NCT04493411

Multiple Myeloma

TERMINATED NA

89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

NCT01859234

Multiple Myeloma

UNKNOWN NA

Imaging in MGUS, SMM and MM

NCT01237054

Multiple Myeloma Smoldering Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance

COMPLETED PHASE2

Diagnostic Imaging of Myeloma Bone Lesions

NCT03147326

Multiple Myeloma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Newly Diagnosed Multiple Myeloma (NDMM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newly diagnosed Mulitple myeloma (NDMM) patients

Patients who recently received the diagnosis multiple myeloma and who will start a standard of care treatment consisting of induction chemotherapy and autologous stem cell transplantation (ASCT), followed by maintenance therapy.

If a patient has already started therapy, it is still possible to be included in the study if following conditions are met: whole body FDG PET/LDCT scan at diagnosis and obtaining at least a very good partial response (VGPR) before start of maintenance therapy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Transplant-eligible newly diagnosed multiple myeloma based on current IMWG criteria and scheduled for induction chemotherapy followed by ASCT. Remark: patiënts can also be included after ASCT, prior to maintenance therapy, if a baseline FDG-PET CT scan showing FDG avid disease is available.
* Baseline 18F-FDG PET/WBLDCT scan should be performed before start of treatment (preferably) or within 7 days after start of treatment. Scan must show FDG avid disease (=at least 1 FL ≥ DS3 and/or diffuse bone marrow involvement).
* WHO performance status 0-2 (WHO \> 2 can be allowed if due to underlying disease and after discussion with the physician).
* Age ≥ 18 years
* Life expectancy \> 12 months, based on clinical judgement.

Eligibility criteria for the primary endpoint

* achieving at least a VGPR after induction chemotherapy and ASCT according to the standard IMWG response criteria.
* received at least one (28-day) cycle of lenalidomide as maintenance therapy after ASCT. No new therapy can be given until clinical relapse.

Exclusion Criteria

* Any physical or physiological condition that may affect adherence to the study protocol, e.g. severe claustrophobia or the inability to lie still for 30 minutes.
* uncontrolled diabetes
* History of concomitant presence of any other malignancy, except for:

* non-melanoma skin cancer
* carinoma in situ of the cervix
* any other effectively treated malignancy that has been in remission for \> 5 years or that is highly likely to be cured at the time of enrollment.
* pregnant or breastfeeding
* refusal or inability to provide written informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No